US Food & Drug Administration (USFDA) had conducted an inspection of Aurobindo Pharma’s Unit IV, a general injectable formulation manufacturing facility situated at Pashamylaram (Hyderabad) from November 4 to 13, 2019. At the end of the inspection, it was issued 'Form 483' with 14 observations.